Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia

News Hour:

Novo Nordisk  presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly greater for Xultophy® (IDegLira) compared to up-titration with insulin glargine U100 in adults with type 2 diabetes uncontrolled on insulin glargine U100 (20-50 units).

Xultophy® is the first once-daily combination of a long-acting insulin (insulin degludec) and a glucagon-like peptide-1 (GLP-1) receptor agonist (liraglutide) in Europe. Results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.1 The post-hoc analysis of the DUAL V phase 3b trial was evaluated using a FPG target of 7.2 mmol/L, selected to better reflect targets used in clinical practice.2 Data showed that adults treated with Xultophy® were 4.55 times more likely to reach FPG targets without confirmed hypoglycaemia and weight gain vs up-titration with insulin glargine U100 (41.4% vs 14.3%, p<0.0001).

The data also demonstrated that significantly more adults achieved HbA1c target of <7% with no hypoglycaemia and no weight gain across baseline HbA1c groups (≤7.5, >7.5– ≤8.5 and >8.5%) with Xultophy® vs up-titration with insulin glargine U100 (51% vs 25%; 39% vs 11%; 32% vs 5%; p<0.005 for all).

In addition, FPG and HbA1c were already significantly reduced at weeks 4, 8 and 12 in adults switching to Xultophy® vs up-titration with insulin glargine U100, demonstrating better glycaemic control shortly after transferring to Xultophy® compared to insulin glargine U100.

“This analysis of DUAL V indicates that Xultophy® is effective in helping patients achieve glycaemic control with a lower risk of hypoglycaemia and weight gain compared to up- titration with insulin glargine U100, based on targets used in clinical practice,” said Dr. Ildiko Lingvay, Associate Professor of Internal Medicine and Clinical Science at UT Southwestern Medical Center.

“The data demonstrate improvements in glycaemic control as early as four weeks after treatment initiation.” Also presented at EASD, Novo Nordisk announced results from DUAL VI demonstrating that using a simpler titration algorithm of once-weekly dose adjustments compared to the twice-weekly adjustments used in previous DUAL trials, results in a non-inferior safety and glycaemic efficacy profile for Xultophy® in insulin-naïve adults with type 2 diabetes.

Md. Rafiuzzaman Sifat, a CSE graduate turned into journalist, works at News Hour as a staff reporter. He has many years of experience in featured writing in different Bangladeshi newspapers. He is an active blogger, story writer and social network activist. He published a book named 'Se Amar Gopon' inEkushe boi mela Dhaka 2016. Sifat got a BSc. from Ahsanullah University of Science & Technology, Bangladesh. He also works as an Engineer at Bangla Trac Communications Ltd. As an avid traveler and a gourmet food aficionado, he is active in publishing restaurant reviews and cutting-edge articles about culinary culture.
No Comments